The stock of Smith & Nephew plc ADR (NYSE:SNN) last traded at $21.91, down -1.44% from the previous session.
Data from the available sources indicates that Smith & Nephew plc ADR (NYSE:SNN) is covered by 17 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $39.40 and a low of $25.04, we find $33.25. Given the previous closing price of $22.23, this indicates a potential upside of 49.57 percent. SNN stock price is now -13.28% away from the 50-day moving average and -23.54% away from the 200-day moving average. The market capitalization of the company currently stands at $9.53B.
In total, 8 analysts have assigned it a hold rating, and 7 have given it a buy rating. Brokers who have rated the stock have averaged $32.88 as their price target over the next twelve months.
Insiders disposed of 525 shares of company stock worth roughly $11502.75 over the past 1 year. A total of 0.04% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SNN stock. A new stake in Smith & Nephew plc ADR shares was purchased by CLEAR STREET MARKETS LLC during the first quarter worth $812,000. SUSQUEHANNA INTERNATIONAL SECURITIES, LTD. invested $811,000 in shares of SNN during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in Smith & Nephew plc ADR valued at approximately $655,000. Y-INTERCEPT (HONG KONG) LTD acquired a new stake in SNN for approximately $617,000. MARSHALL WACE, LLP purchased a new stake in SNN valued at around $549,000 in the second quarter. In total, there are 262 active investors with 8.73% ownership of the company’s stock.
With an opening price of $22.17 on Wednesday morning, Smith & Nephew plc ADR (NYSE: SNN) set off the trading day. During the past 12 months, Smith & Nephew plc ADR has had a low of $22.09 and a high of $33.08. As of last week, the company has a debt-to-equity ratio of 0.58, a current ratio of 2.19, and a quick ratio of 0.83. The fifty day moving average price for SNN is $25.16 and a two-hundred day moving average price translates $28.62 for the stock.
The latest earnings results from Smith & Nephew plc ADR (NYSE: SNN) was released for Jun, 2023. The net profit margin was 4.02% and return on equity was 4.14% for SNN.
Moreover, the firm recently paid out its quarterly dividend on 11/01/2023. Investors who held shares on 10/06/2023 were paid a $0.288 dividend. On an annualized basis, this represents a $0.74 dividend and a 3.39% percent yield. There was an ex-dividend date of 10/05/2023 for this dividend. In terms of dividend payout ratio, SNN is presently at 142.72%.
Smith & Nephew plc ADR(SNN) Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
